Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2021

View Archived Issues

Cyclin C controls responses to PARP inhibitor treatment in BRCA2-deficient cells

LSD1 as potential therapeutic target in heart failure

Antibe places its AME study of otenaproxesul on required pause

First patient dosed in a phase I study of ARX-517

CytomX Therapeutics describes auristatin-related compounds

New PD-1/PD-L1 interaction inhibitors synthesized at Abbisko Therapeutics

Bristol Myers Squibb patents CD80/PD-L1 and/or PD-1/PD-L1 interaction inhibitors

Disarm Therapeutics discovers NAD(+) hydrolase SARM1 inhibitors

ALZ-201 neutralizes the neurotoxicity of postmortem brain extracts from patients with AD

Serum miRNA451a levels are increased in Alzheimer's disease patients

Telmisartan reduces morbidity and mortality in hospitalized patients with COVID-19

ALG-1007 study meets all primary and secondary endpoints

Nordic Nanovector resets expected timeline for phase IIb PARADIGME study of Betalutin

U.S. phase II dosing begins with LUT-014 to reduce EGFR inhibitor-induced acneiform lesions

Phase IIb study of eliapixant in refractory chronic cough meets primary efficacy outcome

Phase I/II trial cleared to begin in Singapore with ARCT-154 and ARCT-165 for SARS-CoV-2

Lumosa reports phase IIa data on LT-3001 in patients after acute ischemic stroke

FDA clears IND for phase Ib study of camsirubicin in advanced soft tissue sarcoma

GTB-5550 TriKE promotes NK cell killing in preclinical testing

South Korea's MFDS clears IND for phase I study of ABL-501 in solid tumors

Phase IIb/III ALLEGRO trial of ritlecitinib in alopecia areata meets primary efficacy endpoint

New study is both reality check and shot in the arm for SARS-CoV-2 drug repurposing

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...